With ubituximab, a high percentage of patients maintained no signs of disease activity.

Published Date: 01 Mar 2023

After receiving ublituximab treatment, the majority of patients with relapsing multiple sclerosis showed that they could achieve and maintain no evidence of disease activity.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Veterans of the Navy have high lung cancer rates associated with asbestos use.

2.

Added Plinabulin Boosts OS as Later-Line Treatment for EGFR Wild-Type NSCLC

3.

In MDS at Lower Risk, Novel Therapy Diminished Transfusion Dependency.

4.

FDA Expands Durvalumab Label to Operable Lung Cancer

5.

Study: One-week breast cancer radiotherapy proven as safe and effective as standard three-week treatment


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot